[ARQL] ArQule, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.29 Change: 0.03 (2.38%)
Ext. hours: Change: 0 (0%)

chart ARQL

Refresh chart

Strongest Trends Summary For ARQL

ARQL is in the long-term up 693% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: ArQule, Inc., a clinical-stage biotechnology company, researches and develops cancer therapeutics. Its lead product candidate tivantinib is an inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase 3 clinical trial for the treatment of non-small cell lung and liver cancer; and Phase 2 clinical trial for the treatment of colorectal cancer. The company?s early clinical-stage products include ARQ 092, an inhibitor of the Akt protein kinase; ARQ 087, a multi-kinase inhibitor with pan-fibroblast growth factor receptor activity; ARQ 761, a NQ01 inhibitor; ARQ 621, an inhibitor of the Eg5 kinesin motor protein; and ARQ 736, an inhibitor of the RAF kinases. It has partnership agreement with Daiichi Sankyo Co., Ltd. and Kyowa Hakko Kirin Co., Ltd. for implementing a clinical development program designed to realize the potential of tivantinib as a single agent; and in combination with other anti-cancer therapies in various disease indications. In addition, the company has research

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.36 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -4% Sales Growth - Q/Q-7.63% P/E-3.11
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-37.6% ROE-56.49% ROI
Current Ratio3.3 Quick Ratio Long Term Debt/Equity Debt Ratio0.45
Gross Margin Operating Margin-191.68% Net Profit Margin-183.06% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities15.23 M Cash From Operating Activities-7.55 M Gross Profit
Net Profit-4.55 M Operating Profit-4.82 M Total Assets55.32 M Total Current Assets55.08 M
Total Current Liabilities16.7 M Total Debt Total Liabilities18.5 M Total Revenue2.79 M
Technical Data
High 52 week7.03 Low 52 week2.26 Last close6.78 Last change-3.56%
RSI59.42 Average true range0.4 Beta1.25 Volume304.8 K
Simple moving average 20 days7.21% Simple moving average 50 days20.09% Simple moving average 200 days47.28%
Performance Data
Performance Week5.61% Performance Month6.94% Performance Quart98.83% Performance Half84.74%
Performance Year98.83% Performance Year-to-date144.77% Volatility daily3.84% Volatility weekly8.58%
Volatility monthly17.58% Volatility yearly60.9% Relative Volume733.06% Average Volume1.57 M
New High New Low

News

2020-01-13 09:34:24 | ArQule, Inc. ARQL vs. Top 20 Hedge Fund Stocks in 2019

2020-01-06 11:07:00 | Moore Kuehn, PLLC Encourages Investors of KEM, ARQL, THOR, and LOGM to Contact the Firm

2019-12-30 06:48:00 | SHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: ARQL, BOLD, THOR

2019-12-28 14:00:10 | THOR, ARQL, TIF, and AMTD SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts

2019-12-24 11:05:00 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - THOR, ARQL, LOGM

2019-12-23 18:45:00 | SHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: ARQL, BOLD, THOR

2019-12-23 16:12:40 | Pharma M&A Deals Likely To Be Smaller in 2020

2019-12-23 09:00:10 | LOGM, ARQL, TIF, and BOLD SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts

2019-12-21 17:29:00 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - CRCM, TCBI, ARQL

2019-12-18 18:45:00 | SHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: ARQL, BOLD, THOR

2019-12-17 18:50:00 | SHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: ARQL, BOLD, KEM

2019-12-16 18:45:00 | SHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: ARQL, BOLD, KEM

2019-12-16 08:00:10 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – ARQL, KEM, CBPX, TECD

2019-12-12 15:49:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates ArQule, Inc.

2019-12-12 13:19:18 | SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of the Following Mergers

2019-12-11 16:16:38 | Why Merck, Sanofi News Helped This Biotech Rocket 32% Over Three Days

2019-12-11 15:15:00 | URGENT NEWS: Monteverde & Associates PC Continues its Legal Inquiry for the Recent Buyout

2019-12-11 07:21:31 | The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint

2019-12-10 18:53:00 | SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of ArQule, Inc. - NasdaqGS: ARQL

2019-12-10 16:31:00 | Investors shift attention to next generation of CAR-T, new sickle cell treatments at major hematology meeting

2019-12-10 16:16:09 | Why Biotech ETFs are Surging to New Highs

2019-12-10 11:57:00 | SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of ArQule, Inc - ARQL

2019-12-10 10:10:03 | Biotech ETFs Hit New Highs on Deal Activities

2019-12-10 09:42:02 | Merck to Buy ArQule for $2.7B to Boost Cancer Portfolio

2019-12-10 09:07:02 | Company News for Dec 10, 2019

2019-12-10 08:27:01 | Pharma M&As Continue, Merck, Sanofi to Buy Cancer Drug Firms

2019-12-10 07:56:02 | The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares

2019-12-09 17:23:00 | Drug manufacturers have spent a record $342 billion on M&A in 2019

2019-12-09 16:45:00 | U.S. stock market snaps 3-day win streak as China tariff deadline comes in focus

2019-12-09 16:23:05 | Why This $2.7 Billion Merck Takeover Could Pressure J&J, Eli Lilly

2019-12-09 16:18:02 | US STOCKS-Wall St falls as Apple, health shares drag, tariff deadline looms

2019-12-09 13:19:45 | US STOCKS-Wall Street drops as tariff deadline looms

2019-12-09 13:15:00 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of ArQule, Inc. to Merck & Co., Inc. is Fair to Shareholders

2019-12-09 13:08:59 | PreMarket Prep Recap: Small Biotech Firms Looking Healthy, Street Fades Macy's Downgrade

2019-12-09 13:04:00 | ARQULE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ARQL and Encourages Investors to Contact the Firm

2019-12-09 12:10:00 | ARQULE, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

2019-12-09 12:03:27 | Benzinga Pro's Top 5 Stocks To Watch For Mon., Dec. 9, 2019: MRK, PCG, M, DPLO, CHWY

2019-12-09 11:59:58 | ArQule Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of ArQule, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ARQL

2019-12-09 11:51:28 | Merck to buy Massachusetts cancer drug developer for $2.7 billion

2019-12-09 11:38:10 | US STOCKS-Wall Street treads water with tariff deadline in focus

2019-12-09 10:49:08 | US STOCKS-S&P 500, Nasdaq edge higher; tariff deadline in focus

2019-12-09 10:44:47 | Drug Giants Pay Hefty Premiums as Cancer-Drug Race Heats Up

2019-12-09 10:16:03 | Week Begins with Biotech Mergers

2019-12-09 10:06:03 | Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More

2019-12-09 09:59:32 | Merck drops $2.7B on 26-year-old Burlington biotech

2019-12-09 09:42:00 | Merck and Sanofi Are Both Acquiring Cancer-Drug Developers

2019-12-09 09:17:43 | Stocks - Canopy Growth, ArQule Rise in Premarket; Microsoft Edges Lower

2019-12-09 08:57:35 | US STOCKS-Wall St set to drop after weak Chinese data; Tariff deadline looms

2019-12-06 14:50:59 | Hedge Funds Are Starting To Cash Out Of ArQule, Inc. ARQL

2019-12-02 08:57:40 | Shareholders Are Raving About How The ArQule NASDAQ:ARQL Share Price Increased 623%